患有COVID-19的家族性高胆固醇血症患者-有效的降胆固醇疗法在感染期间和感染后都很紧急

相关实验视频

Updated: Jun 18, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.1K

Alpo Vuorio^1,2, Frederick Raal³, Petri T Kovanen⁴

¹Mehiläinen Airport Health Centre, 01530 Vantaa, Finland.

Reviews in cardiovascular medicine

|July 30, 2024

概括

异构性家族高胆固醇血症 (HeFH) 患者在COVID-19的情况下面临心脏病发作和中风的更高风险. 加强降胆固醇治疗对于在SARS-CoV-2感染期间和之后管理这些风险至关重要.

科学领域:

心脏病学心脏病学
传染性疾病传染性疾病
遗传学是一个遗传学.

背景情况:

异构性家族性高胆固醇血症 (HeFH) 导致过早动脉样硬化和内皮功能障碍.
患有HeFH的患者对心血管事件的脆弱性增加,包括急性心肌梗塞 (AMI) 和缺血性中风.
在HeFH中,内皮功能障碍因SARS-CoV-2感染而加剧,导致COVID-19预后较差.

研究的目的:

为了突出SARS-CoV-2感染的HeFH患者中AMI和缺血性中风的风险增加.
强调先前存在的内皮功能障碍在HeFH中的作用,作为严重COVID-19结果的预测因素.
为了强调有效的胆固醇管理在减轻COVID-19相关心血管风险对于HeFH患者的重要性.

主要方法:

对美国大型国家数据库的分析.
在有或没有SARS-CoV-2感染的HeFH患者之间,对AMI的年均发病率 (AIDR) 的比较.
审查关于HeFH,内皮功能障碍和SARS-CoV-2影响的现有文献.

主要成果:

与对照组相比,感染SARS-CoV-2的HeFH患者显示AMI的AIDR显著增加.
在HFH患者中,先前存在的内皮功能障碍增加了对SARS-CoV-2引起的血管损伤的易感性.
未经治疗的HeFH会导致早期动脉样硬化,增加心血管风险.

结论:

HeFH是一种显著的并发症,预测COVID-19患者的预后较差.
在SARS-CoV-2感染期间和之后,强化降胆固醇治疗对HEFH患者至关重要.
持续或升级的降脂治疗对于预防或减轻COVID-19在HFH中的有害心血管影响至关重要.

关键词:

在 COVID-19 疫情中,PCSK9 抑制剂的使用.动脉样硬化心血管疾病内皮质功能障碍内皮质功能障碍家庭性高胆固醇血症是什么?类药物类药物类药物

相关概念视频

01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

613

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

613

01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

152

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

152

01:24

Cystic Fibrosis: Management

151

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

151

01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation